"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial of TG01 with GM-CSF and gemcitabine for people who have had surgery to remove cancer of the pancreas
This trial looked at a vaccine called TG01 with GM-CSF and gemcitabine for cancer of the pancreas. This trial was for people who had surgery to completely remove their pancreatic cancer.
It was open for people to join between 2013 and 2016. The team presented the results at a conference in 2017 and published the results in 2020.
More about this trial
In this trial they looked at a vaccine called TG01. It is a type of
In this trial everyone also had GM-CSF.
The aims of this trial were to find out:
- about the side effects of TG01, GM-CSF and gemcitabine
- if this treatment can delay or reduce the chances of your cancer coming back
- what the immune response is after having TG01, GM-CSF and gemcitabine together
Summary of results
The trial team found that:
- the immune system responded well to TG01 with GM-CSF
- the combination of TG01, GM-CSF and gemcitabine was well tolerated
About this trial
This was a phase 1/2 trial. 32 people took part. After the first 19 people the team changed the dosing of the TG01 vaccine.
Everyone taking part started the TG01 and GM-CSF as soon as possible after surgery to remove their pancreatic cancer. They had TG01 and GM-CSF:
- when they were having the gemcitabine
- every month for a year after finishing gemcitabine and then
- every 3 months for another year
There were 10 very serious side effects reported. Gemcitabine caused 6 of these side effects.
The serious side effects included:
- a drop in red blood cells (
- lung infection
- blood clot on the lung
- a mini stroke (TIA)
- 2 people who had a high temperature (fever)
TG01 caused 3 of the serious side effects. All were allergic reactions. Of which 2 were very serious reactions (anaphylaxis).
The treatment for the allergic reaction was steroid tablets and
The other serious side effect was shortness of breath. This was possibly caused by all the treatments.
Other side effects of TG01 included:
- reaction at the site of injection such as redness, itching and swelling
- flu-like symptoms
Response of the immune system
The team used 2 different tests to find out how the immune system responded to TG01 and GM-CSF.
The first test was the delayed-type hypersensitivity (DETH) test. You have TG01 as an injection under the skin. The team looked at the injection site 2 days later to see if there was any redness or a lump. They measured the reaction and if it was at least 5 mm across it meant the immune system had responded. They did the DETH test at least 9 times on everyone.
The second test used blood samples. Everyone gave blood:
- before treatment
- twice during treatment and
- at the end of the trial
In the lab the team looked for T cells in the samples. T cells are a type of white blood of the immune system. They help fight infections and cancer.
Particular T cells are made in response to vaccines such as TG01. The team looked for these T cells. They then divided this number of T cells with the number of T cells that weren’t made due to the vaccine. They considered the immune system had responded if there were at least twice as many of the particular T cells due to TG01.
The team confirmed there was an immune response if either or both tests showed a reaction at least once. Of the 32 people, 30 people’s immune system responded.
How well TG01 worked
Each year for 3 years after treatment the team looked at the number of people who were still living. They found it was:
- 30 people at 1 year
- 23 people at 2 years
- 12 people at 3 years
The team looked at other trials that used chemotherapy only. They found that the length of time people survived was similar. They said that this might suggest TG01 with GM-CSF and chemotherapy could have a combined effect.
The trial team concluded that:
- the response of the immune system to TG01 with GM-CSF is suitable
- the side effects in combination with gemcitabine are acceptable
- they have identified a dosing schedule for the TG01 vaccine
Other clinical trials have shown that combination chemotherapy after surgery increases the length of time people live with pancreatic cancer. But as their cancer still comes back there is a need for further treatment choices. Based on the results of this trial the team suggest that the TG01 vaccine might be very useful in this situation.
Where this information comes from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor Dan Palmer
NIHR Clinical Research Network: Cancer